Anti-inflammatory Treatment of Uveitis with Biologicals: New Treatment Options That Reflect Pathogenetic Knowledge of the Disease

Overview

Journal Graefes Arch Clin Exp Ophthalmol

Specialty Ophthalmology

Date 2010 Aug 26

PMID 20737162

Citations 16

Authors

Arnd Heiligenhaus

Stephan Thurau

Maren Hennig

Rafael S Grajewski

Gerhild Wildner

Affiliations

Soon will be listed here.

Abstract

Background: Endogenous uveitis is a sight-threatening disease. In addition to corticosteroids, immunosuppressive agents are commonly used to treat patients with severe course. Immunosuppressive drugs act nonspecifically, rather than providing a specific interaction with the critical pathogenetic pathways of uveitis. Better knowledge of the basic mechanisms underlying uveitis and of the molecules that are important for regulating inflammation has helped to create new and more specific treatment approaches. Biological therapy for inflammatory diseases employs substances that interfere with specific molecules or pathways induced in the body during the inflammatory process.

Methods: This review gives an overview on molecules that play a critical role in the pathogenetic process of uveitis, as has been observed in patients or the respective animal models, and summarizes the current experience with biologicals for the treatment of uveitis refractive to conventional immunosuppressives.

Citing Articles

Signaling mechanisms of growth hormone-releasing hormone receptor in LPS-induced acute ocular inflammation.

Liang W, Ren J, Yu Q, Li J, Ng T, Chu W Proc Natl Acad Sci U S A. 2020; 117(11):6067-6074.

PMID: 32123064 PMC: 7084074. DOI: 10.1073/pnas.1904532117.

Tolerance Induction in Relation to the Eye.

Gery I, Caspi R Front Immunol. 2018; 9:2304.

PMID: 30356688 PMC: 6189330. DOI: 10.3389/fimmu.2018.02304.

Theissenolactone C Exhibited Ocular Protection of Endotoxin-Induced Uveitis by Attenuating Ocular Inflammatory Responses and Glial Activation.

Lin F, Ho J, Cheng Y, Chiou G, Yen J, Chang H Front Pharmacol. 2018; 9:326.

PMID: 29686615 PMC: 5900795. DOI: 10.3389/fphar.2018.00326.

Intraocular DHODH-inhibitor PP-001 suppresses relapsing experimental uveitis and cytokine production of human lymphocytes, but not of RPE cells.

Diedrichs-Mohring M, Niesik S, Priglinger C, Thurau S, Obermayr F, Sperl S J Neuroinflammation. 2018; 15(1):54.

PMID: 29467002 PMC: 5822610. DOI: 10.1186/s12974-018-1088-6.

[DOG and BVA guideline no. 24b : Noninfectious uveitis posterior].

Ophthalmologe. 2017; 114(12):1122-1134.

PMID: 29159575 DOI: 10.1007/s00347-017-0582-z.

References

Takemura S, Klimiuk P, Braun A, Goronzy J, Weyand C . T cell activation in rheumatoid synovium is B cell dependent. J Immunol. 2001; 167(8):4710-8. DOI: 10.4049/jimmunol.167.8.4710. View

Simonini G, Zannin M, Caputo R, Falcini F, De Martino M, Zulian F . Loss of efficacy during long-term infliximab therapy for sight-threatening childhood uveitis. Rheumatology (Oxford). 2008; 47(10):1510-4. DOI: 10.1093/rheumatology/ken298. View

Weber J . Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist. 2007; 12(7):864-72. DOI: 10.1634/theoncologist.12-7-864. View

Ohsugi Y, Kishimoto T . The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2008; 8(5):669-81. DOI: 10.1517/14712598.8.5.669. View

Sen H, Levy-Clarke G, Faia L, Li Z, Yeh S, Barron K . High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis. Am J Ophthalmol. 2009; 148(5):696-703.e1. PMC: 2922905. DOI: 10.1016/j.ajo.2009.06.003. View

Rothova A, Berendschot T, Probst K, van Kooij B, Baarsma G . Birdshot chorioretinopathy: long-term manifestations and visual prognosis. Ophthalmology. 2004; 111(5):954-9. DOI: 10.1016/j.ophtha.2003.09.031. View

Wilson S, Kent S, Patton K, Orban T, Jackson R, EXLEY M . Extreme Th1 bias of invariant Valpha24JalphaQ T cells in type 1 diabetes. Nature. 1998; 391(6663):177-81. DOI: 10.1038/34419. View

Foxman E, Zhang M, Hurst S, Muchamuel T, Shen D, Wawrousek E . Inflammatory mediators in uveitis: differential induction of cytokines and chemokines in Th1- versus Th2-mediated ocular inflammation. J Immunol. 2002; 168(5):2483-92. DOI: 10.4049/jimmunol.168.5.2483. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

10.

Ishizu T, Osoegawa M, Mei F, Kikuchi H, Tanaka M, Takakura Y . Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005; 128(Pt 5):988-1002. DOI: 10.1093/brain/awh453. View

11.

Sharma S, Ramanan A, Riley P, Dick A . Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis. 2006; 66(6):840-1. PMC: 1954647. DOI: 10.1136/ard.2006.065441. View

12.

Amadi-Obi A, Yu C, Liu X, Mahdi R, Clarke G, Nussenblatt R . TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med. 2007; 13(6):711-8. DOI: 10.1038/nm1585. View

13.

Iwanami K, Matsumoto I, Tanaka-Watanabe Y, Inoue A, Mihara M, Ohsugi Y . Crucial role of the interleukin-6/interleukin-17 cytokine axis in the induction of arthritis by glucose-6-phosphate isomerase. Arthritis Rheum. 2008; 58(3):754-63. DOI: 10.1002/art.23222. View

14.

Tabbara K, Al-Hemidan A . Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease. Am J Ophthalmol. 2008; 146(6):845-50.e1. DOI: 10.1016/j.ajo.2008.09.010. View

15.

Tognon S, Graziani G, Marcolongo R . Anti-TNF-alpha therapy in seven patients with Behcet's uveitis: advantages and controversial aspects. Ann N Y Acad Sci. 2007; 1110:474-84. DOI: 10.1196/annals.1423.050. View

16.

Kurz P, Suhler E, Choi D, Rosenbaum J . Rituximab for treatment of ocular inflammatory disease: a series of four cases. Br J Ophthalmol. 2009; 93(4):546-8. DOI: 10.1136/bjo.2007.133173. View

17.

Deeg C, Raith A, Amann B, Crabb J, Thurau S, Hauck S . CRALBP is a highly prevalent autoantigen for human autoimmune uveitis. Clin Dev Immunol. 2008; 2007:39245. PMC: 2246040. DOI: 10.1155/2007/39245. View

18.

Perkins D, Wang Z, Donovan C, He H, Mark D, Guan G . Regulation of CTLA-4 expression during T cell activation. J Immunol. 1996; 156(11):4154-9. View

19.

Kotter I, Zierhut M, Eckstein A, Vonthein R, Ness T, Gunaydin I . Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003; 87(4):423-31. PMC: 1771623. DOI: 10.1136/bjo.87.4.423. View

20.

Hamzaoui K, Hamzaoui A, Guemira F, Bessioud M, Hamza M, Ayed K . Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol. 2002; 31(4):205-10. DOI: 10.1080/030097402320318387. View